Dr. Akil Abid Merchant, MD

Dr. Merchant practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Merchant's NPI, 1821074857, was assigned on December 21, 2005. Dr. Merchant graduated from Baylor College Of Medicine in 2000. Dr. Merchant's California license number on file is C55368.

Dr. Merchant's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Merchant's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center. Dmand AI also links Dr. Merchant to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Merchant practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Merchant's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Merchant is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Merchant's licenses on file in 3 states: California, Maryland and Texas.

Dmand AI lists fluid and electrolyte imbalances and lymphoma among the conditions Dr. Merchant treats.

CMS data shows 223 Medicare services from Dr. Merchant across 5 procedure codes in 2024, for 57 Medicare patients. Medicare paid $21,812 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 57 Medicare patients who saw Dr. Merchant in 2024. The largest group is 65 to 74, with 32 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 37% are also on Medicaid. Their average risk score is 2.91, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Merchant's median patient age at 67, with 53% women.

In 2024, Dr. Merchant wrote 89 Medicare Part D claims for 19 patients. 82% of them were for generic drugs. CMS names the drug for 59 of them, across 4 drugs with 11 or more claims each, at $755 in total drug cost. In 2019, CMS named 11 claims across 1 drug.

Dr. Merchant accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Merchant as offering telehealth.

Dmand AI links 19 papers to Dr. Merchant, published from 2010 to 2025. 2019 was the busiest year, with 3. The most frequent topics are Leukemia, Myeloid, Acute. Dr. Merchant's most frequent co-authors are Geoffrey W. Chan, MD, Anjali S. Advani, MD and Ryan D. Cassaday, MD.

Dmand AI links Dr. Merchant to 11 clinical trials, 5 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid and Burkitt Lymphoma. Helsinn Healthcare SA sponsors the most, 2. Open Payments lists research payments to Dr. Merchant that name 1 trial.

CMS Open Payments shows 202 general payments to Dr. Merchant from 13 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 72% of the total. Bristol-Myers Squibb Company paid the most, $71,269. It also lists 48 research payments totaling $71,777 from 2016 to 2023, naming 1 clinical trial.

Dr. Merchant graduated from Baylor College Of Medicine in 2000.

Dr. Merchant is in network with 13 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.